Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More
Xconomy
SEPTEMBER 30, 2016
Who will be first to market with a new type of cancer treatment known as CAR-T? TOP STORIES : —Kite Pharma (NASDAQ: KITE ) released data from an ongoing non-hodgkin lymphoma trial that, while early, bolster the view that the Santa Monica, CA, company could be the first to market with a cell-based immunotherapy product known as CAR-T.
40 
Let's personalize your content